Review: Nicotine replacement therapy increases CVD events; bupropion and varenicline do not

@article{Rowland2014ReviewNR,
  title={Review: Nicotine replacement therapy increases CVD events; bupropion and varenicline do not},
  author={K. Rowland},
  journal={Annals of Internal Medicine},
  year={2014},
  volume={160},
  pages={JC2}
}
  • K. Rowland
  • Published 2014
  • Medicine
  • Annals of Internal Medicine
Question Do smoking cessation therapies (nicotine replacement therapy [NRT], bupropion, and varenicline) increase risk for cardiovascular (CV) events? Review scope Included studies assessed NRT (any marketed dose or combination) or licensed doses of bupropion or varenicline for any duration as cessation therapy in smokers and reported CVD events. Outcomes were any CV event and major adverse CV events (MACE) (CV death, nonfatal myocardial infarction, and nonfatal stroke). Review methods MEDLINE… Expand
1 Citations

References

SHOWING 1-3 OF 3 REFERENCES
Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis
TLDR
Available trials indicate that nicotine replacement therapy is an effective intervention in achieving sustained smoking abstinence for smokers who have no intention or are unable to attempt an abrupt quit. Expand
Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis
TLDR
This meta-analysis—which included all trials published to date, focused on events occurring during drug exposure, and analysed findings using four summary estimates—found no significant increase in cardiovascular serious adverse events associated with varenicline use. Expand
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis
TLDR
A systematic review and meta-analysis of randomized controlled trials to ascertain the serious adverse cardiovascular effects of varenicline compared with placebo among tobacco users raises safety concerns about the potential for an increased risk ofserious adverse cardiovascular events associated with the use of v Karenicline among Tobacco users. Expand